In CIH disease models, HIF-1 promotes Angptl4-mediated dyslipidemia and upregulates the expression of Angptl4, which, in turn, inhibits LPL activity and catalytic function, resulting in hyperlipidemia [23]. Here, LPL is linked to metabolic syndrome.